Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that showed significant improvement of atopic dermatitis (AD). Many reports have shown significant resolution of alopecia areata, alopecia universalis, and alopecia totalis after dupilumab treatment for AD. We present one of the few reported cases that showed improvement of underlying alopecia universalis treated with dupilumab.
AbstractAtopic dermatitis (AD) is a common dermatological disorder in children, which is chronic and of a relapsing nature. It is very common in children, with a fair chance of lifetime prevalence of the disease. The following case is of a child 5 months of age who was suffering from AD since 2 months of age. After the first prescription, complaints were much improved. Following that, the child was treated with complex homoeopathic medicines by another physician, which aggravated the condition. Following stoppage of medicines due to an aggravation, a second remedy was thereafter prescribed that provided long-term relief to the patient.
Improvement of atopic dermatitis and alopecia universalis with dupilumab: a case report
